Across TCGA pan-cancer cohorts, EBF4 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated EBF4 data layer compared with 25 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EBF4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EBF4 expression acts as an unfavorable survival marker.
LUAD are the cancer types where EBF4 mass-spec protein most reproducibly stratifies survival.